While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business ...

CEO Guido Oelkers highlighted an 8% growth in Q4 revenues, driven primarily by hematology sales, and an adjusted EBITDA margin of 34%. He noted strong demand for Altuvoct and Vonjo, with Altuvoct ...

The price you pay for Beyfortus may depend on factors such as your child’s dosage and whether you have health insurance. Financial assistance may be available to help you with the cost of Beyfortus.

Q4 guidance included expanded metrics for 2025, such as mid to high single-digit sales growth and low double-digit EPS growth, compared to a more cautious outlook in Q3. Management also introduced a ...

In addition to revenue growth, AstraZeneca's core earnings per share climbed 44% to $2.09. Research and development spending ...

Sanofi SA (SNY) reports robust sales growth driven by Dupixent and vaccines, while planning a significant share buyback to ...

Sanofi has announced an increase in net income from continuing operations for the fourth quarter (Q4) of 2024, reaching €880m ...

Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with acquisitions in the near term as the drugmaker moves towards selling a large ...

The beyfortus market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX ...

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter 2024. Fourth Quarter 2024 Total revenue increased ...